DX 0386Alternative Names: DX-0386
Latest Information Update: 19 Jul 2016
At a glance
- Originator DermaXon
- Class Skin disorder therapies
- Mechanism of Action Retinoic acid metabolism modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Ichthyosis
Most Recent Events
- 19 Jul 2016 Early research in Ichthyosis in USA (unspecified route)